Sangamo Therapeutics, Inc. (SGMO)
Market Cap | 66.42M |
Revenue (ttm) | 18.76M |
Net Income (ttm) | -328.05M |
Shares Out | 207.51M |
EPS (ttm) | -1.86 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,559,370 |
Open | 0.332 |
Previous Close | 0.330 |
Day's Range | 0.313 - 0.350 |
52-Week Range | 0.290 - 1.670 |
Beta | 1.35 |
Analysts | Buy |
Price Target | 5.17 (+1,515.12%) |
Earnings Date | Aug 6, 2024 |
About SGMO
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm... [Read more]
Financial Performance
In 2023, SGMO's revenue was $176.23 million, an increase of 58.34% compared to the previous year's $111.30 million. Losses were -$257.83 million, 34.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is $5.17, which is an increase of 1,515.12% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/b/m/press4-2422512.jpg)
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS.
![](https://cdn.snapi.dev/images/v1/3/c/press16-2421615.jpg)
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing.
![](https://cdn.snapi.dev/images/v1/c/q/conf7-2407707.jpg)
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast.
![](https://cdn.snapi.dev/images/v1/0/n/conf10-2384257.jpg)
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Neurology Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at ASGCT.
![](https://cdn.snapi.dev/images/v1/i/q/press20-2337297.jpg)
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES PRICING OF $24.0 MILLION REGISTERED DIRECT OFFERING.
![](https://cdn.snapi.dev/images/v1/4/o/press9-2322011.jpg)
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results.
![](https://cdn.snapi.dev/images/v1/p/w/press11-2322014.jpg)
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO ANNOUNCES DATA FROM PROPRIETARY NEUROTROPIC AAV CAPSID DEMONSTRATING INDUSTRY-LEADING BLOOD-BRAIN BARRIER PENETRATION & BRAIN TRANSDUCTION.
![](https://cdn.snapi.dev/images/v1/q/m/conf3-2321199.jpg)
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast.
![](https://cdn.snapi.dev/images/v1/3/l/press12-2271281.jpg)
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA ALIGNMENT ON ABBREVIATED PATHWAY TO POTENTIAL APPROVAL AND EMA PRIME ELIGIBILITY FOR ST-920 IN FABRY DISEASE.
![](https://cdn.snapi.dev/images/v1/i/f/press19-2261016.jpg)
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY DISEASE SHOWING SUSTAINED BENEFIT AND DIFFERENTIATED SAFETY PROFILE.
![](https://cdn.snapi.dev/images/v1/r/r/press3-2134146.jpg)
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS.
![](https://cdn.snapi.dev/images/v1/b/a/conf7-2121050.jpg)
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast.
![](https://cdn.snapi.dev/images/v1/d/8/conf19-2116539.jpg)
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg Research at ESGCT.
![](https://cdn.snapi.dev/images/v1/2/l/conf9-2071854.jpg)
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit.
![](https://cdn.snapi.dev/images/v1/x/s/press14-2012992.jpg)
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2023 FINANCIAL RESULTS.
![](https://cdn.snapi.dev/images/v1/l/n/conf7-2000045.jpg)
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES SECOND QUARTER 2023 CONFERENCE CALL AND WEBCAST.
![](https://cdn.snapi.dev/images/v1/6/m/press9-1980040.jpg)
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
BRISBANE, Calif. & BOSTON--(BUSINESS WIRE)--SANGAMO THERAPEUTICS AND CHROMA MEDICINE ANNOUNCE OPTION AND LICENSE AGREEMENT TO EVALUATE AND DEVELOP ZINC FINGER PROTEINS FOR EPIGENETIC EDITING.
![](https://cdn.snapi.dev/images/v1/z/k/press1-1973705.jpg)
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (“Sangamo”, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Thera...
![](https://cdn.snapi.dev/images/v1/s/h/press17-1953056.jpg)
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
BRISBANE, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties ...
![](https://cdn.snapi.dev/images/v1/5/s/press20-1901163.jpg)
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ISARALGAGENE CIVAPARVOVEC FOR THE TREATMENT OF FABRY DISEASE.
![](https://cdn.snapi.dev/images/v1/k/g/press17-1892039.jpg)
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF LISA ROJKJAER, M.D., AS CHIEF MEDICAL OFFICER.
![](https://cdn.snapi.dev/images/v1/o/0/image42-1884834.jpg)
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May - Bio-Rad Laboratories (NYSE:BIO), Accolade (NASDAQ:ACCD)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/r/x/conf15-1866970.jpg)
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO PRESENT PRE-CLINICAL DATA FROM ITS GENOMIC ENGINEERING PLATFORM AT ASGCT.
![](https://cdn.snapi.dev/images/v1/l/d/press15-1856496.jpg)
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS.
![](https://cdn.snapi.dev/images/v1/c/o/conf19-1844639.jpg)
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial resu...